Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

{
  "signal_id": "53cbc679-7de4-2a39-97fd-16fda64afcbf",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-05T15:20:00+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-just-won-third-152000112.html",
    "title": "Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - finance.yahoo.com",
    "excerpt": "Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying off. The company has received three Food and Drug (FDA) approvals over the past four months, and not coincidentally, its shares are up more than 21% so far this year, nearly doubling the S&P 500 index's rise. The most recent approval was on Aug. 27 for Bixlenvo as a daily pill to treat virologically suppressed adults with HIV. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a \"Double Down\" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same \"Total Conviction\" signal is flashing for a company 1/100th the size of Nvidia. Continue » Prior to that, on June 24, Trodelvy received two new approvals to treat triple-negative breast cancer. On May 22, the FDA granted Hepcludex accelerated approval to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. Despite the stock's rise and all the good news on the pipeline front, Gilead may be underrated. There are three reasons why I feel that is the case. Multiple myeloma therapy anito-cel could begin generating revenue as early as the end of this...",
    "product": "Yeztugo",
    "summary": "Gilead Sciences is developing Yeztugo, a once-weekly oral HIV pre-exposure prophylaxis (PrEP) with a PDUFA target date of Feb. 2.",
    "planning": true,
    "image_url": "https://s.yimg.com/lo/mysterio/api/bae2eb5c725651a1b11f8466756a1577fd2fec35480cdc1059a547d041c003e7/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fmotleyfool.com%2F632d7532758bbba214328281f3ab9568.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Yeztugo",
      "full_text": "once-weekly oral Yeztugo for HIV pre-exposure prophylaxis (PrEP)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-05T15:20:00Z",
    "effective_date": "2027-02-02",
    "article_sentence": "The PDUFA target date for once-weekly oral Yeztugo for HIV pre-exposure prophylaxis (PrEP) is set for Feb. 2."
  }
}

curl https://signals.autobound.ai/v1/signals/53cbc679-7de4-2a39-97fd-16fda64afcbf \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'